Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models

por Jain, Mukul R, Giri, Suresh R, Trivedi, Chitrang, Bhoi, Bibhuti, Rath, Akshyaya, Vanage, Geeta, Vyas, Purvi, Ranvir, Ramchandra, Patel, Pankaj R
Publicado 2015

Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, hig...

por Giri, Suresh R., Bhoi, Bibhuti, Trivedi, Chitrang, Rath, Akshyaya, Rathod, Rohan, Sharma, Anish, Ranvir, Ramchandra, Kadam, Shekhar, Ingale, Kailash, Patel, Hiren, Nyska, Abraham, Jain, Mukul R.
Publicado 2023

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease

por Kumar, Divya P., Caffrey, Rebecca, Marioneaux, Jonathon, Santhekadur, Prasanna K., Bhat, Madhavi, Alonso, Cristina, Koduru, Srinivas V., Philip, Binu, Jain, Mukul R., Giri, Suresh R., Bedossa, Pierre, Sanyal, Arun J.
Publicado 2020

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

por Jain, Mukul R., Giri, Suresh R., Bhoi, Bibhuti, Trivedi, Chitrang, Rath, Akshyaya, Rathod, Rohan, Ranvir, Ramchandra, Kadam, Shekhar, Patel, Hiren, Swain, Prabodha, Roy, Sib Sankar, Das, Nabanita, Karmakar, Eshani, Wahli, Walter, Patel, Pankaj R.
Publicado 2017